The evolution of COVID-19 varies from asymptomatic forms to severe manifestations or even death. The main risk factors identified are male gender, old age, diabetes, cardiovascular disease, obesity. Patients with chronic obstructive pulmonary disease (COPD) are also in the risk group due to impaired lung function and being prone to viral exacerbations. The aim of the research was to review the scientific international literature on COPD influence in SARS-CoV-2 pneumonia severity. We analized relevant publications from the PubMed, Scholar Google, NCBI and Medscape databases by using the following search terms : SARS-CoV-2, COVID-19, pneumonia, COPD. The information was systematized, highlighting the peculiarities of SARS-CoV-2 pneumonia in COPD patients. COPD was found in 3-8% of patients diagnosed with pneumonia due to SARS-CoV-2. COPD leads to an increased risk of hospitalization and carry an odds ratio of 2.681 for admission to intensive care units, invasive mechanical ventilation and death. The susceptibility to COVID-19 in patients with COPD may be caused by the overexpression of angiotensin- converting enzyme 2-receptor into the bronchial epithelium and lung tissue due to smoking. As in the case of other comorbidities, COPD patients experienced endothelial cell dysfunction and increased coagulation, which was demonstrated by elevated levels of Ddimers during exacerbations. The role of inhaled corticosteroids (ICS) in COVID-19 remains uncertain. The ICS could play a protective role by reducing the expression of angiotensin-converting enzyme 2-receptor and inflammation, but at the same time, they lead to immunosuppression and increased risk of pneumonia. Also, patients with COPD tend to be older and have multiple comorbidities asociated with poorer outcomes. COPD patients are amongst the worst affected by COVID-19, but it is still uncertain whether COPD itself is associated with a less favorable prognosis, or it is because of older age and important comorbidities often found in these patients.